Hepatits B Vaccine (233961 Sci-B-Vac-002)

The primary objective of the study is to verify that the manufacturing equivalence of Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose regimen of Sci-B-Vac™ to a three-dose regimen of Engerix-B® in adults.

https://clinicaltrials.gov/ct2/show/NCT03408730?term=Sci-B-Vac-002&rank=1

Register Today!.

Trial Information

Start Date18 April 2018
End Date19 May 2019
Trial Duration1 Year
Number of Visits6 In-Person
Lead CRCAdam Pawluch
StatusComplete

For additional information
on this trial contact:

Phone705-566-0005